SRPT
Sarepta Therapeutics, Inc.
80.44
USD
This page is just a preview of the data found in TrendSpider’s full version
Sarepta Therapeutics, Inc. stock is up 19.51% since 30 days ago. The next earnings date is Feb 27, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 11 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 80% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 20 Nov 16:23 | 19 Jan, 2024 | 100.00 | 1300 | ||
| 20 Nov 19:57 | 15 Dec, 2023 | 70.00 | 495 | ||
| 20 Nov 19:57 | 15 Dec, 2023 | 70.00 | 495 | ||
| 21 Nov 20:01 | 21 Jun, 2024 | 100.00 | 26 | ||
| 27 Nov 17:35 | 01 Dec, 2023 | 80.00 | 164 | ||
| 28 Nov 15:51 | 16 Feb, 2024 | 95.00 | 480 | ||
| 28 Nov 18:56 | 15 Aug, 2025 | 65.00 | 0 | ||
| 28 Nov 20:04 | 15 Dec, 2023 | 95.00 | 2045 | ||
| 29 Nov 19:33 | 21 Jun, 2024 | 115.00 | 25 | ||
| 29 Nov 20:29 | 15 Mar, 2024 | 65.00 | 779 |
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio.
